Productivity and deadweight losses due to relapses of schizophrenia in Japan
Authors Nakamura Y, Mahlich J
Received 26 March 2017
Accepted for publication 13 April 2017
Published 17 May 2017 Volume 2017:13 Pages 1341—1348
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Miao Sun
Peer reviewer comments 2
Editor who approved publication: Dr Taro Kishi
Yusuke Nakamura,1 Jörg Mahlich1,2
1Health Economics, Janssen Pharmaceutical K.K., Tokyo, Japan; 2Düsseldorf Institute for Competition Economics (DICE), University of Düsseldorf, Düsseldorf, Germany
Background: No study has examined the financial impact of relapses on schizophrenia from the perspective of Japanese society. This study aimed to estimate the societal costs in Japan caused by the relapses of schizophrenia.
Methods: The societal costs in Japan in 2013 due to relapses of schizophrenia were estimated by summing the productivity loss and deadweight loss caused by schizophrenia relapses in 2013. Deterministic sensitivity analysis was conducted for deadweight loss rate, relapse rate, and patient income.
Results: Japan incurred JPY 55,039 million societal costs because of relapses in 2013. This consists of JPY 3,990 million for productivity loss and JPY 51,049 million for deadweight loss. Rate of deadweight loss is the most significant cost driver in the sensitivity analysis.
Conclusion: Relapses of schizophrenia could generate huge amount of societal costs by reducing labor productivity and economic efficiency. To curb these costs, relapse prevention is desired in treating schizophrenia.
Keywords: schizophrenia, relapses, societal costs, productivity loss, deadweight loss, Japan
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other articles by this author:
Mahlich J, Sruamsiri R
Published Date: 5 August 2016
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
Mahlich J, Nishi M, Saito Y
Published Date: 22 May 2015
A potential gender bias in assessing quality of life – a standard gamble experiment among university students
Al Obaidi L, Mahlich J
Published Date: 24 April 2015
Kuwabara H, Saito Y, Mahlich J
Published Date: 1 April 2015